Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

PD-1 blockade (nivolumab) efficacy remains modest for metastatic sarcoma. In this paper, we present an open-label, non-randomized, non-comparative pilot study of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, with nivolumab in refractory sarcoma at Memorial Sloan Kettering/MD...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Angelo, Sandra P., Richards, Allison L., Conley, Anthony P., Woo, Hyung Jun, Dickson, Mark A., Gounder, Mrinal, Kelly, Ciara, Keohan, Mary Louise, Movva, Sujana, Thornton, Katherine, Rosenbaum, Evan, Chi, Ping, Nacev, Benjamin, Chan, Jason E., Slotkin, Emily K., Kiesler, Hannah, Adamson, Travis, Ling, Lilan, Rao, Pavitra, Patel, Shreyaskumar, Livingston, Jonathan A., Singer, Samuel, Agaram, Narasimhan P., Antonescu, Cristina R., Koff, Andrew, Erinjeri, Joseph P., Hwang, Sinchun, Qin, Li-Xuan, Donoghue, Mark T. A., Tap, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203519/
https://www.ncbi.nlm.nih.gov/pubmed/35710741
http://dx.doi.org/10.1038/s41467-022-30874-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203519/
https://www.ncbi.nlm.nih.gov/pubmed/35710741
http://dx.doi.org/10.1038/s41467-022-30874-8

Ejemplares similares